L
Longeveron Inc. (LGVN)
NCM – Real Time Price. Currency in USD
0.92
-0.05 (-5.44%)
At close: Mar 27, 2026, 4:00 PM EDT
0.91
-0.01 (-1.35%)
After-hours: Mar 27, 2026, 7:58 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
0.92
-0.05 (-5.44%)
At close: Mar 27, 2026, 4:00 PM EDT
0.91
-0.01 (-1.35%)
After-hours: Mar 27, 2026, 7:58 PM EDT
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
| Name | Position |
|---|---|
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Executive Chairman |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer |
| Mr. Brian G Rash Ph.D. | Vice President of Research & Discovery |
| Mr. Devin Blass | CTO and Senior VP of Chemistry, Manufacturing & Controls |
| Mr. Paul T. Lehr J.D. | General Counsel & Secretary |
| Mr. Stephen H. Willard Esq. | Chief Executive Officer |
| Ms. Lisa McClain-Moss | Vice President of Manufacturing |
| Date | Type | Document |
|---|---|---|
| 2026-03-17 | 10-K | lgvn-20251231.htm |
| 2026-03-12 | 8-K | ea0281100-8k_longeveron.htm |
| 2026-03-09 | 8-K | ea0280382-8k_longeveron.htm |
| 2025-11-12 | 8-K | ea0264640-8k_longeveron.htm |
| 2025-11-04 | 8-K | ea0263460-8k_longever.htm |
| 2025-10-01 | 8-K | ea0259742-8k_longever.htm |
| 2025-09-26 | 8-K | ea0258323-8k_longever.htm |
| 2025-09-19 | 8-K | ea0257855-8k_long.htm |
| 2025-09-03 | 8-K | ea0255905-8k_longeveron.htm |
| 2025-08-13 | 10-Q | lgvn-20250630.htm |
| Ms. Lisa A. Locklear M.B.A. |
| CFO, Executive VP & Treasurer |